Venezuela and Russia sign agreements for the local production of insulin and vaccines

Published at: 09/04/2026 04:02 PM

Venezuela and Russia have formalized a strategic alliance with the objective of promoting the transfer of technology for the production of insulin and various biological products in Venezuelan territory.

The agreement provides for the modernization of the facilities of the Socialist Company for the Production of Biological Drugs (Espromed BIO) and the supply of medical products to strengthen the national public health system, according to a press release from the Ministry of Health (MPPS) replicated by the Venezuelan News Agency (AVN).

The technical cooperation carried out through the Russian pharmaceutical company Geropharm and the MPPS involves two operational phases: the first guarantees the total supply of ready-to-use insulin from St. Petersburg to Venezuela, while the second phase consists of the adaptation of local facilities for the autonomous production of ampoules, cartridges and injector pens.

As part of these bilateral relations, the country received a shipment of 1.5 million doses of insulin, which meet the demand of diabetic patients enrolled in state assistance programs.

In addition, health authorities confirmed the arrival of 70,000 doses of the BCG vaccine, destined for the National Plan for Children's Immunization, framed by scientific exchange protocols between the two nations.

The agreement includes a training program for health professionals. In this regard, Russian and Venezuelan specialists have given refresher seminars on integrated diabetes management and on the use of biosimilar drugs at the Latin American School of Medicine (ELAM). These technical meetings aim to standardize treatment protocols and ensure the correct application of the transferred technology.

Beyond the endocrine field, the recently signed protocols expand cooperation to the development of vaccines and cancer treatments.

The implementation schedule foresees that Espromed BIO will be responsible for the local production of chemical components, reducing dependence on imports and consolidating a biotechnology platform in the region.

Mazo News Team